Cost minimization analysis of a hexavalent vaccine in Argentina.
Cost-minimization
Diphtheria
Haemophilus influenza type B
Health outcomes
Hepatitis B
Pediatric
Pertussis
Polio
Tetanus
Vaccination
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
13
12
2022
accepted:
15
09
2023
medline:
1
11
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
Argentina currently uses a pentavalent vaccine containing diphtheria, tetanus, pertussis (whole cell), Haemophilus influenza type b and hepatitis B antigens, administered concomitantly with the inactivated polio vaccine (IPV) (DTwP-Hib-HB plus IPV) in its childhood vaccination schedule. However, hexavalent vaccines containing acellular pertussis antigens (DTaP-Hib-HB-IPV) and providing protection against the same diseases are also licensed, but are only available with a private prescription or for high-risk pre-term infants in the public health program. We analyzed the cost of switching from the current schedule to the alternative schedule with the hexavalent vaccine in Argentina, assuming similar levels of effectiveness. The study population was infants ≤ 1 year of age born in Argentina from 2015 to 2019. The analysis considered adverse events, programmatic, logistic, and vaccine costs of both schemes from the societal perspective. The societal costs were disaggregated to summarize costs incurred in the public sector and with vaccination pre-term infants in the public sector. Costs were expressed in 2021 US Dollars (US$). Although the cost of vaccines with the alternative scheme would be US$39.8 million (M) more than with the current scheme, these additional costs are in large part offset by fewer adverse event-associated costs and lower programmatic costs such that the overall cost of the alternative scheme would only be an additional US$3.6 M from the societal perspective. The additional cost associated with switching to the alternative scheme in the public sector and with the vaccination of pre-term infants in the public sector would be US$2.1 M and US$84,023, respectively. The switch to an alternative scheme with the hexavalent vaccine in Argentina would result in marginally higher vaccine costs, which are mostly offset by the lower costs associated with improved logistics, fewer separate vaccines, and a reduction in adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Argentina currently uses a pentavalent vaccine containing diphtheria, tetanus, pertussis (whole cell), Haemophilus influenza type b and hepatitis B antigens, administered concomitantly with the inactivated polio vaccine (IPV) (DTwP-Hib-HB plus IPV) in its childhood vaccination schedule. However, hexavalent vaccines containing acellular pertussis antigens (DTaP-Hib-HB-IPV) and providing protection against the same diseases are also licensed, but are only available with a private prescription or for high-risk pre-term infants in the public health program. We analyzed the cost of switching from the current schedule to the alternative schedule with the hexavalent vaccine in Argentina, assuming similar levels of effectiveness.
METHODS
METHODS
The study population was infants ≤ 1 year of age born in Argentina from 2015 to 2019. The analysis considered adverse events, programmatic, logistic, and vaccine costs of both schemes from the societal perspective. The societal costs were disaggregated to summarize costs incurred in the public sector and with vaccination pre-term infants in the public sector. Costs were expressed in 2021 US Dollars (US$).
RESULTS
RESULTS
Although the cost of vaccines with the alternative scheme would be US$39.8 million (M) more than with the current scheme, these additional costs are in large part offset by fewer adverse event-associated costs and lower programmatic costs such that the overall cost of the alternative scheme would only be an additional US$3.6 M from the societal perspective. The additional cost associated with switching to the alternative scheme in the public sector and with the vaccination of pre-term infants in the public sector would be US$2.1 M and US$84,023, respectively.
CONCLUSIONS
CONCLUSIONS
The switch to an alternative scheme with the hexavalent vaccine in Argentina would result in marginally higher vaccine costs, which are mostly offset by the lower costs associated with improved logistics, fewer separate vaccines, and a reduction in adverse events.
Identifiants
pubmed: 37803345
doi: 10.1186/s12913-023-10038-0
pii: 10.1186/s12913-023-10038-0
pmc: PMC10557326
doi:
Substances chimiques
Vaccines, Combined
0
Diphtheria-Tetanus-Pertussis Vaccine
0
Poliovirus Vaccine, Inactivated
0
Hepatitis B Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Value Health Reg Issues. 2021 Dec;26:150-159
pubmed: 34474265
Vaccine. 2018 Nov 19;36(48):7270-7275
pubmed: 30337176
Hum Vaccin Immunother. 2015;11(9):2132-41
pubmed: 26075806
Vaccine. 2014 Apr 1;32(16):1778-80
pubmed: 24530935
J Pediatr Health Care. 2008 Sep-Oct;22(5):300-9
pubmed: 18761231
Pharmacoeconomics. 2020 Sep;38(9):995-1005
pubmed: 32596785
Cochrane Database Syst Rev. 2014 Sep 17;(9):CD001478
pubmed: 25228233
MMWR Recomm Rep. 1997 Mar 28;46(RR-7):1-25
pubmed: 9091780
Pediatr Infect Dis J. 2006 Jun;25(6):507-12
pubmed: 16732148
Pediatrics. 1981 Nov;68(5):650-60
pubmed: 7031583
Pediatrics. 2005 Aug;116(2):e285-94
pubmed: 16061582
Wkly Epidemiol Rec. 2015 May 29;90(22):261-78
pubmed: 26027016
Vaccine. 2018 Sep 25;36(40):6007-6016
pubmed: 30143272
Rev Chilena Infectol. 2021 Apr;38(2):224-231
pubmed: 34184714
Front Immunol. 2018 Jan 24;9:51
pubmed: 29416544
Am J Manag Care. 2003 Jan;9(1 Suppl):S6-12
pubmed: 12564784
Vaccine. 2018 Aug 28;36(36):5485-5494
pubmed: 28676382
Vaccine. 2013 Dec 17;32(1):111-8
pubmed: 24176499
Curr Opin Infect Dis. 2020 Oct;33(5):404-410
pubmed: 32773500
Lancet Infect Dis. 2002 Dec;2(12):744-50
pubmed: 12467690
Pediatrics. 1995 Sep;96(3 Pt 2):557-66
pubmed: 7659476
BMC Health Serv Res. 2020 Apr 9;20(1):295
pubmed: 32272920
BMC Health Serv Res. 2022 May 16;22(1):651
pubmed: 35570278
MMWR Morb Mortal Wkly Rep. 2020 Feb 07;69(5):136-139
pubmed: 32027629
Rev Chilena Infectol. 2021 Apr;38(2):232-242
pubmed: 34184715
Vaccine. 2021 Aug 9;39(34):4849-4855
pubmed: 34275672